cancer (CC):. Ann Oncol 2020;31:s1142-1215. 24. Coleman RL, Lorusso D, Gennigens C, et al.: Results
㎡)、长春新碱、泼尼松和CC-122(一种免疫调节治疗的多效途径调节剂)和4周期的鞘内注射甲氨蝶呤治疗。化疗前评估显示左室射血分数(LVEF)为53%,整体纵向应变(GLS)为15.5%(正常(图
alternative macrophage activation–associated cc chemokine-1, cyclooxygenase-1) factors.+/CD16–
associated cc chemokine-1, cyclooxygenase-1) factors.+/CD16--8 and cyclooxygenase--1.-,-9 from human